AzTrials
AzTrials

Laparoscopic GastrectomyNCT06145945

Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy

A study testing 0.5% Ropivacaine and Saline in people with Laparoscopic Gastrectomy and Ropivacaine, run by SanQing Jin at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Visceral pain is obvious and lasts for a long time in patients after laparoscopic gastrectomy.Relieving the visceral pain is of great significance for patients' postoperative emotional experience, functional recovery and reducing the formation of long-term chronic pain. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Laparoscopic Gastrectomy, Ropivacaine
What is being tested?
0.5% Ropivacaine and Saline
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
72 participants
Where
1 siteChina
Study dates
25 Nov 2023to 7 Jul 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-65 years old
  • The American Society of Anesthesiologists(ASA) grade is I or II, and the heart function grade is 1-2;
  • Elective laparoscopic gastrectomy under general anesthesia

Who cannot join

  • Patients have severe heart, lung, liver, and kidney diseases (heart function grade>3 / respiratory failure / liver failure / renal failure)
  • BMI<18kg/m2 or >30kg/m2
  • Patients with chronic pain other than stomach pain and taking analgesics for a long time
  • Patients with history of allergy to local anesthetics
  • Patients with high risk of reflux and aspiration such as digestive obstruction
  • Patients who refuse to participate or don't sign or refuse to sign the informed consent form
  • Patients who are unable to communicate effectively
  • Patients participate in other clinical trials

Trial locations and contacts

1 site in 1 country.

China1 site
  • SanQing Jin

    Guangzhou, Guangdong

    SanQing Jin, MD, 0086-13719366863, sanqingjin@hotmail.com

Other trials in China

About this study

Official title: A Randomized Controlled Study of the Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy

Visceral pain is obvious and lasts for a long time in patients after laparoscopic gastrectomy.Relieving the visceral pain is of great significance for patients' postoperative emotional experience, functional recovery and reducing the formation of long-term chronic pain. However, there is no clear clinical consensus on relieving visceral pain by now, so effective clinical methods to relieve visceral pain need to be explored urgently.

Intraperitoneal spraying local anesthetics is a simple and inexpensive method, which has been proved to be safe and effective in randomized controlled trials and Meta-analysis of various types of surgery.However, its effect in clinical research is still controversial and many studies lack evaluation of postoperative recovery quality, so it has not been widely used in clinical practice.

This study aims to explore the effect of intraperitoneal spraying ropivacaine (long-acting amide local anesthetic) on visceral pain after laparoscopic gastrectomy, and to systematically evaluate its effect on the recovery of gastrointestinal function and the inflammatory factors (IL-6, TNF-α) in abdominal drainage fluid.

Read the detailed description

Postoperative pain is a common adverse reaction after laparoscopic gastrectomy. Insufficient analgesia can cause severe stress response,affect the recovery of postoperative gastrointestinal function, increase the incidence of postoperative complications and prolong the length of hospital stay. Although laparoscopic surgery significantly reduces postoperative pain compared to traditional open surgery, the management of postoperative pain remains a challenge. Postoperative pain after laparoscopic surgery is mainly divided into three parts: incision pain(somatic pain component), deep abdominal pain (visceral pain component) and shoulder pain (referred pain component). In a prospective study, Blichfeldt-Eckhardt et al. found that visceral pain accumulated in the first week after surgery was identified as an independent risk factor for unexplained chronic pain at 12 months after surgery, and visceral pain was the only pain component that was independently and significantly associated with chronic unexplained pain at 12 months after surgery .

Visceral pain is generally defined as pain caused inside the body, but is usually caused by excessive contraction, stretching, or ischemia of the walls of internal organs . In contrast to pain signals originating from the skin,pain originating from the viscera is described as dull and diffuse, often poorly localized, and can be distant from its origin.Visceral pain is considered more unpleasant and frightening than somatic pain.

Therefore,relieving the visceral pain is of great significance for patients' postoperative emotional experience, functional recovery and reducing the formation of long-term chronic pain. However, there is no clear clinical consensus on relieving visceral pain by now, so effective clinical methods to relieve visceral pain need to be explored urgently.

Intraperitoneal spraying local anesthetics is a simple and inexpensive method, which has been proved to be a safe and effective way to reduce the use of opioid and postoperative pain score in randomized controlled trials and Meta-analysis of various surgical types such as laparoscopic cholecystectomy , laparoscopic appendectomy , laparoscopic gynecology and so on. Intraperitoneal spraying local anesthetics is a type of topical anesthesia.Local anesthetics produce local anesthesia by acting on nerve endings on the surface of the visceral organs.Visceral organs mainly transmit nociceptive signals through the vagus nerve and spinal nerve, among which the spinal nerve mainly transmits mechanical stimulation signals, while the vagus nerve mainly transmits chemical stimulation signals. Arman Kahokehr et al. found that intraperitoneal spraying local anesthetics during colectomy may reduce postoperative pain by blocking intra-abdominal vagus nerve signals. At the same time, it inhibits the corresponding neuroendocrine stress pathway, thus resulting in behavioral benefits. However, it does not separately evaluate the different pain components of patients after surgery.

At the same time,the effect of intraperitoneal spraying local anesthetics is still controversial and many studies lack evaluation of postoperative recovery quality,so this technique has not been widely used in clinical practice. Schipper IE et al. spray 20ml 2.5% bupivacaine into the abdominal cavity during laparoscopic gastric bypass surgery, and the test results indicated that the experimental group did not significantly reduce postoperative pain or opioid use, and the use of antiemetic drugs and the length of hospital stay were not significantly reduced.A review in 2021 included 85 clinical trials of intraperitoneal spraying local anesthetics during laparoscopic cholecystectomy, found that intraperitoneal spraying local anesthetics could reduce pain for up to 24 hours in patients undergoing laparoscopic cholecystectomy. However,none of these trials provided postoperation follow-up information and evaluation of postoperative recovery quality.

In this study, pain types are assessed independently to explore whether intraperitoneal spraying local anesthetics could reduce visceral pain by blocking splanchnic nerve afferents. This study will use ropivacaine, the most commonly used long-acting amide local anesthetic, which has low toxicity and an effective acting time of about 4-6 hours.This study set up multiple time points after surgery to evaluate the visceral pain and recovery quality of patients,in order to explore whether early postoperative pain control can slow down or block the formation of postoperative chronic pain, and systematically evaluate the effect of intraperitoneal spraying local anesthetics on the postoperative recovery quality of patients.In a meta-analysis Sparreboom CL et al. found that patients with postoperative anastomotic leakage had significantly higher levels of IL-6 and TNF-α in abdominal drainage fluid at 24h after surgery than those without anastomotic leakage, but this significant change was not observed in blood samples.Wiik et al. reported that inflammatory cytokines are more widely released into the abdominal cavity after abdominal surgery compared with systemic responses,which may be due to the secretion of these cytokines by lymphocytes and monocytes at the site of anastomotic leak.Inflammatory factors are not only related to postoperative anastomotic leakage, but also closely related to the occurrence and development of postoperative pain.Inflammatory stimulation or tissue damage stimulates a cytokine cascade that ultimately triggers the release of mediators that cause inflammatory pain. Immune cells release inflammatory factors such as IL-6 and TNF-α, and induce prostaglandin synthesis and enhance TRP and Nav channel activation through a series of signal transduction pathways, thus inducing inflammatory pain in vivo.Therefore, we plan to detect the inflammatory factors IL-6 and TNF-α in the abdominal drainage fluid at 24h after surgery,to explore the effect of Intraperitoneal spraying local anesthetics on the postoperative abdominal drainage fluid related inflammatory factors, and to evaluate its influence on the recovery of postoperative gastrointestinal function further.

The anesthesia induction protocol for this study includes intravenous titration administration of propofol at a rate of 0.5mg/kg/min, sufentanil 0.3ug/kg, and cisatracurium 0.2mg/kg. Anesthesia is maintained with propofol, remifentanil cisatracurium and sevoflurane to maintain the patient's blood pressure at ±20% of the basic blood pressure and BIS between 40 and 60. The first dose of analgesia and antiemetic (0.3ug/kg sufentanil + 5mg dezocine + 0.25mg palonosetron hydrochloride) is given half an hour before the end of surgery. Before closing the abdominal cavity after abdominal irrigation, 20ml of 0.5% ropivacaine or an equal volume of normal saline is uniformly sprayed onto the surgical area using an endoscopic instrument channel. After skin closure, 10ml of 0.5% ropivacaine is used for infiltration anesthesia at the incision site, and a venous analgesia pump is connected (3ug/kg sufentanil + dezocine 15mg+ palonosetron hydrochloride 0.5mg+NS 120ml). After the surgery, the patient is induced to spontaneous breathe and the tracheal tube will be removed, and then he is sent to the PACU for further observation. If the pain NRS score in the recovery room is greater than 4, a single injection of 5ug sufentanil will be administered until the NRS score is ≤4. When the patient achieve a Sterward score of 6 points, he will be returned to the ward.

Visceral pain is obvious and lasts for a long time in patients after laparoscopic gastrectomy. This study intends to include these patients in the study, and adopt ropivacaine, a local anesthetic with less cardiotoxicity and relatively long acting time,to provide further clinical data for the relief of postoperative visceral pain by intraperitoneal spraying local anesthetics.This study will also systematically evaluate the effect of intraperitoneal spraying local anesthetics on the postoperative recovery quality and the inflammatory factors in postoperative abdominal drainage fluid.

Being tested
0.5% Ropivacaine, Saline
Keywords
visceral pain
Medical subject headings
Visceral Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 0.5% RopivacaineDrug

    Also called Ropivacaine

    20ml 0.5% ropivacaine is sprayed intraperitoneally

  • SalineDrug

    20ml saline is sprayed intraperitoneally

Study groups in NCT06145945
Study groupRoleWhat they receive
RopivacaineExperimental20ml 0.5% ropivacaine is sprayed intraperitoneally
Receives: Drug: 0.5% Ropivacaine
SalinePlacebo comparator20ml saline is sprayed intraperitoneally
Receives: Drug: Saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. NRS scores of visceral pain

    NRS scores of visceral pain at 24 hours after surgery

    Measured: 24 hours after surgery

Secondary outcomes (24)
  1. NRS scores of visceral pain

    NRS scores of visceral pain at 0 hour,1 hour,6 hours,12 hours,the second day,the third day and the 30th day after surgery

    Measured: From surgery completion to the 30th day after surgery

  2. NRS scores of incisional pain

    NRS scores of incisional pain at 0 hour,1 hour,6 hours,12 hours,24 hours,the second day,the third day and the 30th day after surgery

    Measured: From surgery completion to the 30th day after surgery

  3. NRS scores of referred pain

    NRS scores of referred pain at 0 hour,1 hour,6 hours,12 hours,24 hours,the second day,the third day and the 30th day after surgery

    Measured: From surgery completion to the 30th day after surgery

  4. Blood pressure(SBP,DBP,MAP)

    Relative change of blood pressure(SBP,DBP,MAP) at the time of entering the operating room,the beginning of anesthesia,the beginning of surgery and 0 hour,1 hour,6 hours,12 hours,24 hours,the second day,the third day after surgery

    Measured: From the period of anesthesia to the third day after surgery

  5. Heart rate

    Relative change of heart rate at the time of entering the operating room,the beginning of anesthesia,the beginning of surgery and 0 hour,1 hour,6 hours,12 hours,24 hours,the second day,the third day after surgery

    Measured: From the period of anesthesia to the third day after surgery

  6. Oxygen saturation

    Relative change of oxygen saturation at the time of entering the operating room,the beginning of anesthesia,the beginning of surgery and 0 hour,1 hour,6 hours,12 hours,24 hours,the second day,the third day after surgery

    Measured: From the period of anesthesia to the third day after surgery

  7. Additional analgesics in the ward

    Use of additional analgesics in the ward

    Measured: From surgery completion to the third day after surgery

  8. Nausea and vomiting

    Whether nausea and vomiting, the frequency of vomiting

    Measured: From surgery completion to the third day after surgery

  9. Use of intravenous analgesia pump

    The total and effective pressing times of intravenous analgesia pump,total consumption of sufentanil

    Measured: From surgery completion to the third day after surgery

  10. Serum C-reactive protein (CRP) concentration

    Serum C-reactive protein (CRP) concentration

    Measured: One day before surgery and 24 hours after surgery

  11. The level of blood glucose

    The level of blood glucose

    Measured: One day before surgery and 24 hours after surgery

  12. Interleukin-6(IL-6)

    IL-6 concentration in abdominal drainage fluid

    Measured: 24 hours after surgery

  13. Tumor necrosis factor-α(TNF-α)

    TNF-α concentration in abdominal drainage fluid

    Measured: 24 hours after surgery

  14. Postoperative recovery score using 15-item quality of recovery scoring system(QoR-15)

    To evaluate the postoperative recovery using 15-item quality of recovery scoring system including emotional state,body comfort, psychological support, body independence and pain at the first day,the second day,the third day and the 30th day after surgery

    Measured: From the first day to the 30th day after surgery

  15. Anal exhaust time

    The time of first anal exhaust time after surgery

    Measured: From surgery completion to first anal exhaust after surgery,assessed up to 7 days

  16. Sitting up time

    The time of first sitting up time after surgery

    Measured: From surgery completion to first sitting up after surgery,assessed up to 7 days

  17. Getting out of bed time

    The time of first getting out of bed time after surgery

    Measured: From surgery completion to first getting out of bed after surgery,assessed up to 7 days

  18. First drinking time after surgery

    First drinking time after surgery

    Measured: From surgery completion to first drinking after surgery,assessed up to 7 days

  19. First eating time after surgery

    First eating time after surgery

    Measured: From surgery completion to first eating after surgery,assessed up to 7 days

  20. Removal of stomach tube time

    Removal of stomach tube time

    Measured: From surgery completion to removal of stomach tube,assessed up to 30 days

  21. Removal of drainage tube time

    Removal of drainage tube time

    Measured: From surgery completion to removal of drainage tube,assessed up to 30 days

  22. Removal of indwelling urinary catheter time

    Removal of indwelling urinary catheter time

    Measured: From surgery completion to removal of indwelling urinary catheter,assessed up to 30 days

  23. Incidence of postoperative complications within 30 days after surgery

    Incidence of intra-abdominal infection and anastomotic leakage within 30 days after surgery

    Measured: Within 30 days after surgery

  24. Length of hospital stay after surgery

    Hospital stay time from operation completion to actual hospital discharge

    Measured: From surgery completion to actual hospital discharge, assessed up to 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2023
  2. Study start25 Nov 2023 (estimated)
  3. Primary completion3 Mar 2024 (estimated)
  4. Study completion7 Jul 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
72 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06145945
Sponsor's protocol ID
2023ZSLYEC-502
Status last verified
Nov 2023
First submitted
9 Nov 2023
Last updated
28 Nov 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Cha SM, Kang H, Baek CW, Jung YH, Koo GH, Kim BG, Choi YS, Cha SJ, Cha YJ. Peritrocal and intraperitoneal ropivacaine for laparoscopic cholecystectomy: a prospective, randomized, double-blind controlled trial. J Surg Res. 2012 Jun 15;175(2):251-8. doi: 10.1016/j.jss.2011.04.033. Epub 2011 May 17.

    PubMed 21658722
  • Blichfeldt-Eckhardt MR, Ording H, Andersen C, Licht PB, Toft P. Early visceral pain predicts chronic pain after laparoscopic cholecystectomy. Pain. 2014 Nov;155(11):2400-7. doi: 10.1016/j.pain.2014.09.019. Epub 2014 Sep 22.

    PubMed 25250720
  • Feng B, Guo T. Visceral pain from colon and rectum: the mechanotransduction and biomechanics. J Neural Transm (Vienna). 2020 Apr;127(4):415-429. doi: 10.1007/s00702-019-02088-8. Epub 2019 Oct 9.

    PubMed 31598778
  • Boezaart AP, Smith CR, Chembrovich S, Zasimovich Y, Server A, Morgan G, Theron A, Booysen K, Reina MA. Visceral versus somatic pain: an educational review of anatomy and clinical implications. Reg Anesth Pain Med. 2021 Jul;46(7):629-636. doi: 10.1136/rapm-2020-102084.

    PubMed 34145074
  • Koenen LR, Icenhour A, Forkmann K, Pasler A, Theysohn N, Forsting M, Bingel U, Elsenbruch S. Greater fear of visceral pain contributes to differences between visceral and somatic pain in healthy women. Pain. 2017 Aug;158(8):1599-1608. doi: 10.1097/j.pain.0000000000000924.

    PubMed 28426553
  • Rutherford D, Massie EM, Worsley C, Wilson MS. Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomy. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD007337. doi: 10.1002/14651858.CD007337.pub4.

    PubMed 34693999
  • Yong L, Guang B. Intraperitoneal ropivacaine instillation versus no intraperitoneal ropivacaine instillation for laparoscopic cholecystectomy: A systematic review and meta-analysis. Int J Surg. 2017 Aug;44:229-243. doi: 10.1016/j.ijsu.2017.06.043. Epub 2017 Jun 30.

    PubMed 28669869
  • Kang H, Kim BG. Intraperitoneal ropivacaine for effective pain relief after laparoscopic appendectomy: a prospective, randomized, double-blind, placebo-controlled study. J Int Med Res. 2010 May-Jun;38(3):821-32. doi: 10.1177/147323001003800309.

    PubMed 20819419
  • Ruiz-Tovar J, Gonzalez J, Garcia A, Cruz C, Rivas S, Jimenez M, Ferrigni C, Duran M. Intraperitoneal Ropivacaine Irrigation in Patients Undergoing Bariatric Surgery: a Prospective Randomized Clinical Trial. Obes Surg. 2016 Nov;26(11):2616-2621. doi: 10.1007/s11695-016-2142-z.

    PubMed 27007272
  • Gebhart GF, Bielefeldt K. Physiology of Visceral Pain. Compr Physiol. 2016 Sep 15;6(4):1609-1633. doi: 10.1002/cphy.c150049.

    PubMed 27783853
  • Kahokehr A, Sammour T, Zargar Shoshtari K, Taylor M, Hill AG. Intraperitoneal local anesthetic improves recovery after colon resection: a double-blinded randomized controlled trial. Ann Surg. 2011 Jul;254(1):28-38. doi: 10.1097/SLA.0b013e318221f0cf.

    PubMed 21670611
  • Schipper IE, Schouten M, Yalcin T, Algie GD, Damen SL, Smeenk RM, Schouten R. The Use of Intraperitoneal Bupivacaine in Laparoscopic Roux-en-Y Gastric Bypass: a Double-blind, Randomized Controlled Trial. Obes Surg. 2019 Oct;29(10):3118-3124. doi: 10.1007/s11695-019-03982-6.

    PubMed 31201692
  • Sparreboom CL, Wu Z, Dereci A, Boersema GS, Menon AG, Ji J, Kleinrensink GJ, Lange JF. Cytokines as Early Markers of Colorectal Anastomotic Leakage: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2016;2016:3786418. doi: 10.1155/2016/3786418. Epub 2016 Mar 9.

    PubMed 27051416
  • Wiik H, Karttunen R, Haukipuro K, Syrjala H. Maximal local and minimal systemic cytokine response to colorectal surgery: the influence of perioperative filgrastim. Cytokine. 2001 May 7;14(3):188-92. doi: 10.1006/cyto.2001.0870.

    PubMed 11396998
  • Zarbock A, Ley K. Neutrophil adhesion and activation under flow. Microcirculation. 2009 Jan;16(1):31-42. doi: 10.1080/10739680802350104.

    PubMed 19037827

Questions about this trial

What is this clinical trial studying?

A study testing 0.5% Ropivacaine and Saline in people with Laparoscopic Gastrectomy and Ropivacaine, run by SanQing Jin at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 28 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact SanQing Jin, MD (0086-13719366863, sanqingjin@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

NRS scores of visceral pain (time frame: 24 hours after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06145945, which also lists 18 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in